Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Complete response to mTOR inhibitor following JAKi failure in severe pulmonary sarcoidosis: Authors' reply.
Pulmonology
December 2025
AP-HP, Pulmonology Department, Avicenne Hospital, Bobigny, France.
Ultrathin bronchoscopy-guided small airway biopsy for diagnosing sarcoidosis: A prospective study.
Pulmonology
December 2025
Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Hearth, Rome, Italy.
New ultrathin bronchoscopes (UTBs) enable the inspection and biopsy of small airways, potentially offering diagnostic advantages in sarcoidosis. In this prospective study, patients with suspected sarcoidosis underwent airway inspection with a UTB. Observed airway abnormalities were categorised into six predefined patterns.
View Article and Find Full Text PDFCardiac sarcoidosis; update for the heart failure specialist.
Curr Opin Cardiol
January 2025
Division of Cardiology, University of Ottawa Heart Institute, University of Ottawa, Faculty of Medicine, Tier 1 Clinical Research Chair in Cardiac Electrophysiology, Ottawa, ON, Canada.
Purpose Of Review: This review presents contemporary data on epidemiology, common presentations, investigations and diagnostic algorithms, treatment and prognosis. It particularly focuses on topics of most relevance to heart failure specialists, including what left ventricle (LV) function changes can be expected after treatment and outcomes to all standard and advanced heart failure therapies.
Recent Findings: Around 5% of sarcoidosis patients have clinically manifest cardiac sarcoidosis (CS), presenting with significant arrhythmias (such as conduction disturbances and ventricular arrhythmias) or newly developed unexplained heart failure.
Sarcoidosis-Like Reaction in a Patient With Psoriatic Arthritis Treated With Adalimumab.
Cureus
December 2024
Internal Medicine, Hospital Infante D. Pedro, Aveiro, PRT.
A drug-induced sarcoidosis-like reaction (DISR) is a systemic granulomatous reaction indistinguishable from sarcoidosis and is associated with the administration of a medication. It typically exhibits a temporal relationship with the initiation of the drug (an average interval of 22 months) and tends to improve upon its discontinuation. Tumor necrosis factor (TNF) antagonists, including adalimumab, have been associated with the development of DISR.
View Article and Find Full Text PDFUpregulation of HSP90α in the lungs and circulation in sarcoidosis.
Front Med (Lausanne)
January 2025
Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
Background: Sarcoidosis is a systemic granulomatous disease of unknown cause. Natural improvement with favorable outcome is common, but a significant number of patients present with difficult to manage and progressive disease. The identification of biomarkers associated with disease activity and progression is warranted.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!